Biomarker Assay Market Supply Demand 2016-2020

Biomarkers are defined as measurable indicators of a particular disease or condition that are evaluated to diagnose and confirm the presence or absence of regular biological processes, pathogens and efficacy of pharmacological intervention. Biomarkers can be chemicals and compounds that are freely available in the body and are present in greater or lower concentrations as compared with control (normal) state. The concept is used on various disease areas within healthcare and medicine such as oncology, neurology, cardiovascular diseases and genetic diseases. Genetic and protein biomarkers are the largest studied aspects within this sphere. Due to the difficulty in treatment of cancer, the greatest focus of researchers has been on the application of oncology; cancer biomarkers have been commercialized and researched the most today with the biggest database of over 2000 clinically relevant or validated biomarkers being used over the world today.

Research and development of biomarker discovery along with their clinical relevance is a new aspect for the pharmaceutical industry as compared to preclinical and pure research studies. Thus there is a very large latent scope for growth in this area. Technological advancements have provided excellent tools to all healthcare areas for analysis and development of biomarkers. Overall the biomarkers segment can be classified into several types namely, predisposition biomarkers, screening biomarkers, diagnostic biomarkers, predictive biomarkers, pharmacological biomarkers and prognostic biomarkers. Advanced proteomic and genomic analytical techniques have revealed a wide spectrum of mutations and their respective mutated proteins that are highly specific to various cancer types. Today biomarkers are helping medical professionals map out the likely course, stage and grade of various cancers.

Click For Full Report And Request TOC@ http://www.sa-brc.com/Global-Biomarker-Assay-Market-Assessment--Forecast-2016---2020/upcomingdetail33

In terms of applications, cancer biomarkers are available for various types such as lung, breast, prostate, liver, blood, colorectal, cervical, skin and pancreatic cancers. Several commercialized products in the market include BRAF mutation test, K-RAS mutation, EGFR + ALK test, BRCA, HER2, AFP, CA-19-9 & 125, CEA and others such as ROS-1, AKT and NRAS. The market for cancer biomarkers can also be segmented from the perspective of different geographies. This report intends to analyse the market for multiple regions of North America, Europe, Asia-Pacific, Latin America, Middle-East and Africa. In terms of region, North America and Europe lead the market due to a very high rate of diagnoses in the regions. The developed regions also indicate the presence of niche specialty medical expertise in oncology that increases the diagnosis rates as compared to other regions of the world. Along with this, there is also a greater reach of good medical facilities in the developed regions such as United States, United Kingdom, France, Germany and Canada that adds to the prospects. This also represents an excellent opportunity for companies to acquire significant revenues from developing regions as there is a large fraction of cancer cases that go undiagnosed and unscreened for a long duration until the late stages.

The purpose of this report is to analyse the potential of screening and diagnoses of cancer in normal and at-risk people. This study is intended for manufacturers of assay kits, hospitals, medical experts, oncology experts, manufacturers of companion diagnostics and pharmaceutical companies among other avid readers who wish to understand this market. The report will benefit individuals understand the trends of the market in terms of targeted and personalized medicine and its progress. In 2014, the global cancer biomarkers market was estimated to be valued at US$ 8.0 billion and accounts for around 60% of the total biomarkers market. The cancer biomarkers market is expected to grow at a CAGR of 13% due to factors such as rising incidence of the top five cancer types that are breast, colorectal, lung, stomach and prostate. Key players in this area include Qiagen, Affymetrix, Illumina, Ambry Genetics, BioMerieux, Myriad Genetics, OriGene, Genomic Health, Molecular Response, Entrogen, Genoptix, Hoffman-La Roche and a plethora of other regional players.

For More Research Reports@ http://www.sa-brc.com/Medical-Devices/industry1

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
10685-B Hazelhurst Drive,
Suite 17411
Houston, Texas 77043,
United States
Phone: +1(832)-426-3701
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.